|1.||Prostatic Neoplasms (Prostate Cancer)
01/01/1983 - "Cisobitan in treatment of prostatic cancer. "
01/01/1983 - "Of 34 patients with poorly differentiated prostatic cancer 18 were given Cisobitan--and 16 were given Estracyt-treatment. "
01/01/1983 - "In a multicenter study a total of 140 patients with well and moderately well differentiated prostatic cancer were randomly allocated to treatment with Cisobitan or Estradurin/Etivex, 70 to each group. "
01/01/1978 - "It is therefore doubtful whether Cisobitan will be a reasonable alternative to estrogens in the treatment of patients with advanced prostatic cancer."
01/01/1978 - "Thirteen patients with stage III or IV carcinoma of the prostate were treated with 2,6-cis-Diphenylhexamethylcyclotetrasiloxane (Cisobitan, a new organosilicon compound. "
01/01/1978 - "Prostatic carcinoma treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan)."
01/01/1978 - "Two drugs, 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan) and estramustine-17-phosphate (Estracyt) were given to patients with poorly differentiated metastatic carcinoma of the prostate. "
01/01/1983 - "Of the 34 patients with poorly differentiated cancer, twelve were alive at the 24 months' follow up, six in the Cisobitan group and six in the Estracyt group."
01/01/1983 - "Cancer was responsible for the deaths in seven of the Cisobitan patients compared to four of the estrogen treated patients. "
|4.||Body Weight (Weight, Body)
|3.||polyestradiol phosphate (Estradurin)